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Purpose: C-reactive protein (CRP) is an acute phase reactant, involved
in both acute and chronic inﬂammatory diseases. CRP is produced
mainly by the liver upon elevated levels of cytokines such as IL-6. From
the liver CRP is transported back to the inﬂamed tissue where it binds
its receptors and thereby accumulated by the tissue. We have recently
identiﬁed the presence fragments of CRP, generated by matrix metal-
loproteinases (MMPs). These fragments are released from the tissue as
MMPs are upregulated in response to pro-inﬂammatory induction.
Recently, an assay was developed, CRPM, which can measure this tissue
speciﬁc inﬂammation. The aim of the study was to investigate whether
the level of the protein ﬁngerprint CRPM together with the systemic
inﬂammatory marker hsCRP could segregate OA patients with and
without inﬂammatory arthritis.
Methods: High sensitive CRP (hsCRP) and CRPM were measured in the
serum of patients from three OA cohorts; the CCBR (n¼150), the C4P-
003 (n¼250) and the HTF-synovitis (n¼50) studies. The CCBR study
consisted of control subjects and patients with various degrees of
asymptomatic OA (n¼88, KL 1 to 4). The C4P-003 study consisted of
patients with different degree of symptomatic OA as well as controls. All
patients in the HTF-Synovitis study were eligible and referred to total
joint replacement (TJR) and were described as having end stage OA. KL
and VAS pain was monitored for each of the patients. The biomarkers
were plotted against each other (ﬁgure) and cut-offs were set based on
reference value.
Results: Patients were separated into 4 groups; 1) patient with low
CRPM (tissue inﬂammation) and low hsCRP (systemic inﬂammation), 2)
patients with high CRPM and low hsCRP, 3) patients with low CRPM and
high hsCRP, and 4) patients with high CRPM and high hsCRP. 33% of the
patients with end stage OAwere found in group 4, whereas only 22% of
the patients with symptomatic OA segregated to this group. In
comparison, 8% of the asymptomatic OA patients and only 4% of the
controls went in to group 4. More than 70% of the controls segregated to
group 1, whereas more than 60% the asymptomatic OA patients showed
up in group 2. The rest of the patients with symptomatic and end stage
OA were equally distributed to group 2 and 3.
Conclusions:We found that different of the two inﬂammatory markers
could facilitate patient segregation. This may have many implications,
however most importantly in the identiﬁcation of more OA patients
with the right diagnosis, inﬂammatory vs. non-inﬂammatory disease,
which may beneﬁt from a given treatment.Ă136
HYALURONIDASE TREATMENT OF SYNOVIAL FLUID CAN IMPROVE
MEASURED SIGNAL BY MULTIPLEX IMMUNOASSAY PLATFORMS
C. Jayadev, S. Snelling, D. Mahoney, A. Price, P. Hulley. Univ. of Oxford,
Oxford, United KingdomPurpose: Synovial ﬂuid (SF) is an important source of OA biomarkers
since it offers a direct measure of joint pathophysiology. Multiplex
immunoassay technologies i.e. Luminex (LX) and MesoScale Discovery
(MSD) allow high-throughput, multiple parallel analysis of precious
small volume biological specimens. SF analysis is challenging because of
its complex non-homogenous matrix and non-Newtonian nature.
Hyaluronidase (HAse) treatment of SF has been shown to improve intra-
assay precision, particularly on the LX platform. This study assesses the
impact of HAse treatment of SF on measured cytokine concentra-
tions by the LX and MSD platforms.
Methods: 16 SF samples were collected at primary knee arthroplasty for
end-stage OA. All samples underwent identical processing. Aliquots
from each sample were then left untreated (neat), 2-fold diluted (2xD),
4-fold diluted (4xD) or digested with testicular hyaluronidase (HAse,
1200U/ml with effective 2-fold sample dilution). Dilutions and HAse
were made up in the same diluent used for calibrator standard prepa-
ration. SF samples were run in triplicate for each preparation method
tested. Treatment methods were compared in a polysterene-bead
Luminex 10-plex (pLX, N¼16), magnetic-bead Luminex IL6 singleplex
(mLX, N¼7) and MSD 4-plex (N¼7). Treatment methods were assessed
for dilution-adjusted analyte concentration. Percentage recovery was
calculated for dilutions and HAse treatment. A recovery of 10020%was
considered acceptable. Repeated measure statistical tests were used
where possible since every SF sample was treated by each method
under comparison i.e. within-subject experimental design. Nonpara-
metric data was log10 transformed and parametric statistical tests were
used throughout. P<0.05 was considered signiﬁcant. Reported p-values
are for repeatedmeasure tests, but groupmeans and standard deviation
(SD) or 95% conﬁdence intervals (95CI) are given to aid non-graphical
description.
Results: pLX:-Only IL6 and IL8 were above limit of quantiﬁcation (LOQ).
HAse treatment resulted in a signiﬁcantly higher measured concen-
tration of IL-8 (p¼0.027), but did not reach statistical signiﬁcance for IL-
6 (p¼0.061). IL8: 418.2pg/ml (SD 126.4) vs 181.8pg/ml (SD 328.1). IL6:
713pg/ml (SD 646.0) vs 372.9pg/ml (SD 303.5). This was reﬂected in
recoveries of >200% for both analytes after HAse treatment.mLX:- The
dilution adjusted IL-6 concentration was greatest for HAse treated SF
(p<0.001): 483.9pg/ml (SD 576.2) vs neat 155.5pg/ml (SD 211.3) vs 2xD
254pg/ml (SD 327.6) vs 4xD 305.3pg.ml (SD 392.1). There were no
signiﬁcant differences in corrected concentration between neat, 2xD
and 4xD samples. The recovery of HAse treated samples was 316% (95CI
195%-437%) and was signiﬁcantly greater (p¼0.03) than 2xD (149%;
95CI 79%-220%) and 4xD samples (188%; 95CI 82%-293%). Although the
mean dilution recoveries were elevated, the 95%CI for both spanned the
acceptable range.MSD:- Only IL-6 & IL-8 were>LOQ for all samples and
treatments. TNF-awas >LOQ in all neat samples and 6/7 2xD and HAse
treated samples. Therewere no signiﬁcant within-subject differences in
dilution-adjusted concentrations for any analyte between preparation
methods. The recoveries were within 20% of expected for all analytes
irrespective of treatment method and there were no signiﬁcant
differences.
Conclusions: Both LX and MSD show acceptable dilution linearity
during SF analysis. Measured concentrations were higher and recovery
was elevated (poor) after HAse treatment on the LX platforms. There
was no such effect on the MSD platform, which thus seems to be more
resistant to matrix effects.
HAse treatment should be recommended for SF biomarker research,
particularly using the Luminex platform.137
ITRAQ IDENTIFICATION OF THREE NOVEL DIAGNOSTIC MARKERS OF
OSTEOARTHRITIS
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Purpose: Biomarkers are a useful tool for assessment of prognosis and
disease severityof various diseases. Discovery of new biomarkers can
lead to identiﬁcation of therapeutic targets and permit analysis of the
molecular mechanisms of disease. Herein, we performed a compre-
hensive proteomic analysis of articular cartilage to investigate variation
of rare proteins using the isobaric tags for relative and absolute quan-
titation (iTRAQ) method, and searched for upregulated or
